[go: up one dir, main page]

WO1999034217A1 - Reactifs specifiques a st2l et leurs utilisations - Google Patents

Reactifs specifiques a st2l et leurs utilisations Download PDF

Info

Publication number
WO1999034217A1
WO1999034217A1 PCT/GB1998/003913 GB9803913W WO9934217A1 WO 1999034217 A1 WO1999034217 A1 WO 1999034217A1 GB 9803913 W GB9803913 W GB 9803913W WO 9934217 A1 WO9934217 A1 WO 9934217A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
st2l
antibody
thl
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1998/003913
Other languages
English (en)
Inventor
Foo Yew Liew
Damo Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Priority to AU19750/99A priority Critical patent/AU1975099A/en
Publication of WO1999034217A1 publication Critical patent/WO1999034217A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a membrane bound form of ST2 protein known as ST2L protein, particularly the development of reagents specific for ST2L which may be used in cell separation or identification, drug screening and treatment of ailments such as infections, inflammation, and allergy.
  • CD4 + T cells can be divided into Thl and Th2 subsets, the balance of which frequently determines the outcome of infections and autoimmune diseases.
  • Thl cells characteristically produce interferon gamma (IFN- ⁇ ) and activate macrophages to kill intracellular pathogens and can cause inflammatory diseases.
  • Th2 cells produce interleukin (IL)-4 and IL-5 and are associated with allergic reactions involving IgE, eosinophils and basophils [reviewed in Mosmann, T.R. & Coffman, R.L. (1989) Ann. Rev. Immunol. 1, 145-173].
  • IL interleukin
  • ST2L a cDNA encoding a membrane-bound form of the mouse ST2 protein, which was designated "ST2L".
  • ST2L comprises additional 3 ' sequence encoding a transmembrane region and a cytoplas ic region.
  • the amino acid sequence of the extracellular domain of ST2L was found to be 25% identical to the extracellular domain of murine type I IL-1.
  • Yoshida et al (1995) [Hybridoma 14 p419-428], discloses eight species of murine monoclonal antibodies against human ST2 protein. All the antibodies reacted with N- glycosylated ST2 protein secreted from C0S7 cells. The antibodies were found to react with a membrane bound chimeric molecule possessing an extracellular portion of human ST2. The human leukemic cell line UT-7 was also shown to express ST2 protein.
  • the present invention is based in part on the discovery by the present inventors that the ST2L protein is expressed on the surface of certain classes of T cells but not on other T cells.
  • the present inventors have utilised a technique known as differential display-polymerase chain reaction (DD-PCR) , see Liang, P. and Pardee, A.B. (1992) Science 257, 967-971, to identify a gene encoding a cell membrane bound molecule, originally designated ST2L (see Yanagisawa, K. , et al (1993) FEBS 318, 83-87) and expressed constitutively and stably on murine Th2 cells but not on Thl cells. Yanagisawa et al (1997) [J.
  • Biochem 121 p95-103 discloses that murine ST2 and ST2L mRNA are preferentially expressed by Th2 and D10 cells, but not by Thl cells.
  • Studies using the human ST2 protein showed that ST2L was believed to be expressed on the surface of at least one fraction of lymphocytes in peripheral blood mononuclear cells.
  • Yanagisawa et al did not attempt to define which sub- population of lymphocytes expressed ST2L on their surface.
  • the present inventors have also shown a membrane bound form of human ST2 (hereinafter referred to as ST2L in line with the murine protein) to be expressed constitutively and stably on human Th2 cells but not on Thl cells.
  • the inventors have identified the expression of ST2L on type 2 cytotoxic T cells (Tc2) but not Tel cells.
  • ST2L is expressed on type 2 T cells which typically produce IL-4 and IL-5 and not on type 1 T cells which produce IFN- ⁇ .
  • the present description will refer principally to Th2 and Thl cells, but it should be appreciated that the description is not limited thereto and may be similarly equated with Tc2 and Tel cells also.
  • the present invention provides a method for distinguishing cells which express membrane bound ST2L from those that do not, the method comprising contacting a sample of cells with a reagent specific for ST2L and determining the presence or absence of an ST2L/reagent complex.
  • membrane bound ST2L possesses intracellular and extracellular domains as well as a transmembrane region and that the reagent specific for ST2L is generally specific for the extracellular domain.
  • Th2/Thl cells may be distinguished using the above method. Since ST2L is present on Th2 and not Thl cells, the above method distinguishes Th2 cells by the presence of an ST2L/reagent complex and Thl cells by the absence of an ST2L/reagent complex. Thus, such a method may also be used to identify whether or not a sample of activated Th cells are of the Th2 or Thl type. Such a method represents a simple means of distinguishing between Thl and Th2 cells and/or detecting the presence of Th2 cells in a sample.
  • the present invention also provides a method for purifying Thl or Th2 cells from a sample comprising Thl and/or Th2 cells, the method comprising contacting a sample comprising Thl and/or Th2 cells with reagent specific for ST2L, such that any Th2 cells present in the sample bind to the reagent, and removing any. unbound material.
  • Thl cells present in the sample will remain with the unbound material and thereby be purified away from Th2 cells.
  • Th2 cells may be separated from the ST2L specific reagent by washing, eluting or other conventional means of removal, thereby providing a purified sample of Th2 cells.
  • Such a method may also be extended to a sample of cells comprising activated Th cells (ie. Thl or Th2 ) and used to identify such cells and allow their purification.
  • the reagent specific for ST2L may be bound to a substrate such as a plastics substrate, microcarrier beads or a chromatography support media.
  • Another aspect of the invention provides reagents e.g. antibodies, ligands, agonists and/or antagonists capable of specifically binding to ST2L for use in medicine, particularly therapy, prophylaxis or diagnosis.
  • reagents e.g. antibodies, ligands, agonists and/or antagonists capable of specifically binding to ST2L for use in medicine, particularly therapy, prophylaxis or diagnosis.
  • the reagent used for distinguishing and/or purifying Thl/Th2 cells may be an antibody specific for ST2L, more particularly specific for an epitope(s) located on the extracellular domain of ST2L.
  • the antibody is raised against peptides of ST2L which have been judged (eg. by computer analysis) to possess substantially no cross-reactivity with other cellular proteins, such as IL-1 and IL-1 receptor superfamily.
  • antibodies suitable for use in the present invention include antibodies raised against the following peptides of the mouse ST2L protein (numbering according to Yanagisawa et al (1993) FEBS 318, 83-87) GEARIQEEGRNESSSNDMD; (residues 267-287) YSDTNESIPTQKRNR; (residues 56-70) SKSSWGLENEALIVR; (residues 27-41) and in addition, antibodies raised against the following peptides of the human ST2 protein (numbering according to Tetsuka, T. , et al (1992) [Biochim, Biophys. Acta 1171, 215-218] :
  • DFGEPRIQQEEGQNQSFSN (residues 264-282) RRHTVRLSRJNPSKE; (residues 312-327) CLDMVLRIADVKEED; (residues 282-296) YSTVSGSEKNSKIYC; (residues 118-133) CKFIHNENGANYSVT; (residues 181-195) CPRQGKPSYTVDWYYS ; (residues 36-51) SKQS GLENEALIVRCP ; (residues 26-42) YSQTNKSIPTQERNR; (residues 56-70) DLYN TAPLEWFKNCQ; (residues 142-158)
  • the above peptides were identified on the basis of being on the extracellular portion of the ST2L protein, their hydrophilicity and for their uniqueness.
  • the utility of antibodies raised against any of the above peptides may be verified by immunoabsorbance assay and/or by flow cytometry (for more specific details see the examples section) .
  • Such antibodies may be polyclonal antibodies raised in a suitable host, such as a rabbit or monoclonal antibodies produced according to standard protocols, using spleen cells taken from mice immunised with a peptide and fusing with a suitable immortal cell line such as NSO myeloma cells [See for example Golding J.W. (1986) Monoclonal Antibodies: Principles and Practice. Academic Press, London or Winter G. et al Trends in Pharmacol. Sci. 14 : 139-143, 1993].
  • antibody as used herein is intended to include polyclonal or monoclonal antibodies or fragments thereof which are specifically reactive with murine and/or human ST2L or im unogenic fragments thereof.
  • Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example F(ab') 2 fragments can be generated by treating antibody with pepsin. The resulting F(ab') 2 fragment can be treated to reduce disulphide bridges to produce Fab 1 fragments.
  • the antibodies described herein are further intended to include bispecific and chimeric molecules possessing an antigenic determinant to ST2L.
  • the murine monoclonal antibodies may be humanised according to standard techniques [see for example Winter G. et al Trends in Pharmacol. Sci. 14.: 139- 143, 1993].
  • a binding assay such as an immunoassay may be used to distinguish and/or identify Thl/Th2 cells.
  • an immunoassay such as an immunoassay may be used to distinguish and/or identify Thl/Th2 cells.
  • Many different immunoassay techniques are known to the skilled addressee. For example, wells of a microtitre plate (or other suitable solid substrate) can be coated with an antibody which specifically binds ST2L. After a suitable period of incubation with a sample comprising Thl/Th2 cells, Th2 cells will become bound to the antibody, thereby forming an ST2L/antibody complex, thereafter unbound material (such as Thl cells) may be removed by washing, and the amount of ST2L/antibody complex and consequently Th2 cells determined.
  • unbound material such as Thl cells
  • the amount of ST2L/antibody complex may be determined by way of a further antibody specific for the anti-ST2L antibody.
  • the further antibody may be suitably labelled, for example with a fluorescent label, a radiometric label or with an enzyme cleavable substrate, the product of which may be detected.
  • Both monoclonal and polyclonal antibodies directed against ST2L, and antibody fragments described above can be used as reagents to block ST2L function and allow study of, for example, Th cell proliferation or cytokine induction.
  • Antibodies which specifically bind ST2L epitopes can also be used in immunohistochemical staining of body fluid and tissue samples in order to evaluate the abundance or otherwise of Th2 cells.
  • Anti-ST2L can be used diagnostically in flow cytometry to detect and evaluate Th2 levels in body fluid and/or tissue as part of a clinical testing procedure. By monitoring Th2 levels in an individual it is possible to determine the efficiency of a treatment given to an individual afflicted with a disorder associated with Th cell proliferation.
  • Antibodies of the present invention may be used in combination with complement in substantially selectively lysing Th2 cells in preference to Thl cells.
  • the antibodies alone may also be used in vitro or irf vivo to inhibit Th2 cell function.
  • the antibodies may be used to regulate the ratio of Thl:Th2 cells in a host organism or in an in vitro system. Controlling the ratio of Thl:Th2 cells may provide a means with which to control many infections and/or autoimmune diseases.
  • Thl or Th2 cells are implicated in the ailments, such as for afflictions associated with Thl or Th2 cell proliferation or programs for identifying antagonists/agonists of ST2L.
  • Such drug screening programs may be directed to drugs which may ameliorate the ailments and thereby reduce any associated Thl or Th2 cell response.
  • drugs may have a direct action on the Thl or Th2 cells and consequently cause a proliferation or diminution of Thl or Th2 cells.
  • Such drug screening may be carried out in vitro or in vivo and results determined by utilising the antibodies as described herein to ascertain the effect a particular drug has on the ailment by determining Thl/Th2 cell levels.
  • the antibodies of the present invention may themselves be used in therapy, as mentioned above, by controlling the relative proportions of Thl:Th2 cells in a host.
  • the present invention also provides anti-ST2L antibodies for use in therapy and to the use of anti-ST2L antibodies in the manufacture of medicaments for therapy.
  • Th2 cells are the major mediators of allergic reactions, for example in asthma, reducing Th2 cell numbers and/or blocking cell functions via ST2L will be of therapeutic value against such allergic reactions. Moreover, reducing Th2 cell numbers and/or blocking cell function via ST2L may result in a proliferation or perceived increase in the relative proportion of Thl cells.
  • anti-ST2L antibodies are indicated as having application against diseases mediated by intra-cellular pathogens, such as leishmania and inflammatory diseases such as arthritis.
  • spleen cells from D011.10 mice were purified for CD4 + T cell by negative selection as described previously by Openshaw, P. et al. (1995) J. Exp. Med. 182, 1357-1367.
  • the cell lines were cultured with OVA peptide (OVA 323 - 339 ) and irradiated BALB/c spleen cells in the presence of IL-12 plus anti-IL-4 (for Thl cell line) or IL-4 (for Th2 cell line) for 6 days.
  • DD-PCR Differential display-polymerase chain reaction
  • DD-PCR was performed according to Liang, P. and Pardee, A.B. (1992) Science 257, p967-971 using RNAimage kit (GenHunter corporation, Brookline, MA02146, USA) .
  • Total RNA was treated with DNase I (GenHunter Corp.) to remove any trace of DNA.
  • Purified RNA (1 ⁇ g) was transcribed into cDNA using MMLV reverse transcriptase.
  • the cDNA was amplified by using AmpliTaq DNA polymerase (Perkin Elmer) with 50 pairs of primers (GenHunter) .
  • PCR reactions were performed in the presence of [ 3S S]-dATP (NEN, Boston, USA) , and products separated in 6% sequencing gels under denaturing conditions. DNA fragments from Thl and Th2 cells were then compared. Differentially expressed distinct bands longer than 150 bp were excised from the dried gel, extracted by boiling in 100 ⁇ l of dH 2 0, and precipitated with ethanol in the presence of glycogen. The DNA was further amplified with the original set of primers used to generate the particular band, using the same thermal cycle conditions.
  • PCR products were electrophoresed in a 1.5% agarose ethidiu bromide gel to confirm the band size before cloning into PCRII vector (InVitrogen) and sequenced using M13R and M13(-20)F primers. (available from GenHunter Corp. USA) .
  • Reverse Northern blot This was used to screen and confirm the differentially expressed mRNA according to the method described in Zhang, H. , et al (1996) Nucl. Acid Res. 24, 2454-2456 using a ReversePrime Kit (GenHunter Corp.).
  • Denatured PCR products 100 ng were dot-blotted onto duplicate nylon membranes by the slot blot filtration manifolds (Hoefer, San Francisco, CA94107) , using murine IL-5 and ⁇ -actin cDNA as control and equal loading.
  • Membranes were UV cross-linked and hybridised with equal amounts to Thl or Th2 cDNA probes (10 s cpm) .
  • the probes were prepared from 10-50 ⁇ g of RNA from each of the cloned Thl or Th2 cells by reverse transcription, using 1000 units of MMLV reverse transcriptase in the presence of -[ 32 P]dCTP and T20 primer. (available from GenHunter Corp. USA) .
  • the hybridisation patterns of duplicate membranes were then compared .
  • the 3' cDNA fragment was cloned from D10 cells by DD-PCR using the primer pair: AAGCTTTTTTTTTTTA and AAGCTTCAGCAGC
  • RT-PCR Southern Blot Primers for amplifying ST2L were: sense, ACTTTGTTCACCACACTCTGC ; antisense, AACAGATGCCGTCTTGGAGGC (which generate a product of about 450 bp) . Primers for ⁇ -actin were: sense, GTGGGCCGCTCTAGGCACCAA; antisense, CTCTTTGATGTCACGCACGATTTC (which generate a product of about 540 bp) . PCR products were separated in 1% agarose gels.
  • Membranes were hybridised with internal probes (ST2L: ATTGAAATGGAGCCTCTGGGTGAGGCAAGC; ⁇ -actin: CAGAGCAAGAGAGGTATCCTGACCC) labelled with ⁇ -[ 32 P]dATP using T4 polynucleotide kinase.
  • a rabbit was immunised with the peptide corresponding to residues 267-287 of murine ST2L (numbering according to Yanagisawa et al (1993) FEBS Letters 258 , 83-87) .
  • the peptide was conjugated to keyhole limpet haemocyanin (KLH) .
  • KLH keyhole limpet haemocyanin
  • the rabbit was injected with 100 ⁇ g of peptide conjugated to KLH in Freund ' s incomplete adjuvant subcutomeously.
  • the rabbit was boosted four weeks later with the same antigen in incomplete adjuvant.
  • the rabbit was further boosted with an iv injection of 100 ⁇ g of the antigen in saline.
  • the rabbit was bled out one week later.
  • the peptide was selected to have no homology with IL-1 receptor and within the extracellular region of ST2L. Specificity of the antibody was tested by Western blot against recombinant ST2L and by ELISA with peptide-bound 96-well plates. Total IgG was purified from immune serum and pre-immunised serum by protein A column or by Annonium sulphate precipitation according to standard protocols. Purity of the IgG was >95% as determined by SDS-PAGE coomasse blue staining.
  • a further rabbit was immunised with a peptide corresponding to residues 264-282 of human ST2 (numbering according to Tetsuka, T. , et al (1992) Biochi . Biophys. Acta 1171, 215-218) according to the same protocol. Additionally a monoclonal antibody was raised against the same peptide and prepared according to the protocol as set out in Winter et al 1993 [Trends in Pharmacol. Sci. 14 : 139-143] .
  • cells were suspended at 10 5 -10 6 /ml and stimulated with phorbol myristate acetate (PMA, 50 ng/ml, Calbiochem) plus ionomycin (500 ng/ml, Calbiochem) for 4h.
  • PMA phorbol myristate acetate
  • ionomycin 500 ng/ml, Calbiochem
  • Brefeldin A 10 ⁇ g/ml, Sigma
  • Cells were then incubated with anti-ST2L antibody or control IgG followed by biotinylated goat anti-rabbit IgG (DAKO) and then developed with PerCP-streptavidin (Becton Dickinson, USA) . All incubations and washing were carried out at 4°C in PBS containing FCS (5%) and NaN 3 (0.1%).
  • the cells were then fixed with paraformaldehyde (2%) , and, after washing, permeabilised at room temperature with 0.5% saponin (Sigma) in PBS and FCS (5%) , and stained sequentially with FITC- conjugated anti-murine IFN- ⁇ (IgG2a, PharMingen) and phycoerythrin (PE) -conjugated anti-murine IL-4 (IgG2a, PharMingen) , or FITC- and PE- conjugated isotype control antibodies (Becton Dickinson) . Samples were analysed on a FACScan flow cyometer (Becton Dickinson) .
  • Complement-mediated cell lysis Cloned T cell lines (see Table 1) (1x10 s cells in 0.2 ml culture medium) were incubated with various concentrations of anti-ST2L antibody or normal rabbit IgG (clarified by centrifugation) for 30 min on ice. The cells were washed once and then incubated with guinea pig complement (1/10 dilution, Harlan sera-lab, UK) for 45 min at 37°C. Cell viability was estimated microscopically (counting >500 cells) by staining with acridine orange and ethidium bromide according to standard protocols.
  • mice Female, 6-8 weeks old, Harlan Olac, Bicester, UK
  • mice were infected in the right hind footpad with 1x10 s stationary phase promastigotes of Leishmania major (LV39) and injected intra peritoneally (ip) with 250 ⁇ g of rabbit anti-ST2L antibody or normal rabbit Ig.
  • the antibody was administered for the next two days, and then every 3-4 days for 1 week followed by weekly injections.
  • Lesion development was followed by measuring the footpad swelling (difference between the infected right and uninfected left hind footpad) .
  • the maintenance of parasites, infection, and measurement of disease progression were as described previously by Howard et al (1980) [J. Exp. Med.
  • mice were killed by cervical dislocation. Footpad was removed for assay of parasite load by limiting dilution according to McSorley et al (1997) [Infect. Immun. 65, pl71-178]. Draining lymph node cells were harvested and cultured (lxl0 6 /ml) in vitro with frozen and thawed parasite antigen (10 s -10 7 parasite/ml equivalent) . Culture supernatant was harvested at 48 h and assayed for cytokines by ELISA using paired antibodies (PharMingen) . Anti- leishmanial specific antibody in the serum was titrated for IgGl and IgG2a as described previously by McSorley et al (1997) .
  • mice Male DBA/1 mice (6-8 weeks old, Harlan Olac, UK) were injected intradermally with 200 ⁇ g of bovine type II collagen (Sigma) in Freund's complete adjuvant (d-21) . Collagen (200 ⁇ g in PBS) was given again on do by ip injection. Daily injections (ip, 200 ⁇ g/mouse) of anti- ST2L antibody or normal rabbit IgG were administered from dl for 5 days. Mice were monitored daily for signs of arthritis for which severity scores were derived as follows: 0 - normal, 1 - erythema, 2 - erythema + swelling, 3 - extension/loss function, total score - sum of 4 limbs. Paw thickness was measured with a dial-calliper (Kroeplin, Germany) . Quantification of arthritis was performed as previously described [Joosten et al (1997), Arthritis Rheum, 40, 249-260].
  • ST2L band as determined by nucleotide sequencing and comparison with nucleic acid databases.
  • Northern blot analysis demonstrated the constitutive expression of ST2L in all four Th2 but not in Thl clones tested (see Fig. lb) .
  • Thl (X9) and Th2 (DIO) clones were stimulated for 3 , 6 or 12 h with: (see figure 2a) Lane 1, Con A (2.5 ⁇ g/ml); lane 2, IL-l ⁇ ; lane 3, IL-5; lane 4, IL-2 ; lane 5, IL-4 ; lane 6, IFN- ⁇ (all cytokines were recombinant murine proteins obtained from Genzyme used at 5 ng/ml) ; lane 7 anti-IFN- ⁇ (1 ⁇ g/ml); lane 8, anti-IL-4 (1 ⁇ g/ml); lane 9 medium alone; lane 10, anti-CD3 (1.5 ⁇ g/ml).
  • Results for 12 h were the same as for 3 h, except no message was detected in X9.
  • DIO cells expressed ST2L constitutively and stably, whereas X9 cells failed to do so, except a weak and transient response at 3 h and 6 h to IL-5 and anti-CD3 respectively.
  • Thl clones which expressed ST2L constitutively did not express ST2L even when stimulated with concanavalan A (Con A), IL-l ⁇ , IL-2, IL-4 , IFN- ⁇ , or with anti-IFN- ⁇ or anti-IL-4 antibodies.
  • Con A concanavalan A
  • IL-l ⁇ IL-2
  • IL-4 IFN- ⁇
  • anti-IFN- ⁇ anti-IL-4 antibodies.
  • Thl clones expressed a weak ST2L message transiently at 3 and 6 h post-activation respectively (Fig. 2a) ; but this disappeared completely by 12 h.
  • the expression of ST2L in Th2 cells was not affected by these stimuli (Fig. 2a) .
  • ST2L is a delayed, early proliferative response gene in BALB/C-3T3 cells induced by serum factors [Yanagisawa, K., et al (1993) FEBS 318, 83-87], the regulation of ST2L expression in Th clones by serum was examined.
  • Cells were rested for 48 h in serum-free medium and then cultured in medium containing 20% FCS.
  • the expression of ST2L on Th2 clones was diminished when cultured in serum-free medium, but restored soon after the addition of serum.
  • the expression of ST2L in ThO clones was not affected by serum starvation. In contrast, no ST2L message was detectable in Thl clones before or 6 h after addition of serum (see Fig. 2b: X9 (Thl, lane 1), X4 (Thl, lane 2), DIO (Th2, lane 3) and Y8 (ThO, lane 4) .
  • Thl (X4) and Th2 (X12) cells were stained with rabbit anti- ST2L antibody (green) or preimmune rabbit IgG (white) (40 ⁇ g/ml) and developed with a FITC-conjugated donkey anti- rabbit IgG. Stable cell surface staining of Th2 clones but not Thl clones was detected with this antibody (Fig. 3a) . Similar results were obtained for three other Thl and Th2 clones (not shown).
  • ThO (Y8, data not shown) cells had the same staining pattern as Th2 cells.
  • the staining of Th2 cells (X12) with anti-ST2L antibody can also be visualised by fluorescent microscopy (x400) . Staining can be blocked by the ST2L peptide (100 ⁇ g/ml) and no staining was detected on Thl cells (data not shown) .
  • PMA and ionomycin-activated Th2 (X12) and Thl (X4) clones were stained for cell surface ST2L (with PerCP) , followed by intra-cellular staining with anti-IL-4 (with PE) and anti-IFN- ⁇ (with FITC) .
  • Cytokines in the culture supernatants (48 h) of T cell clones (lxl0 6 /ml) stimulated with specific antigen and irradiated antigen presenting cells were (IFN- ⁇ vs IL-4 , ng/ml): X4 , 5.2 vs ⁇ 0.02; X12 , ⁇ 0.01 vs 0.25.
  • Single cell, three colour flow cytometric analysis demonstrated that ST2L co-expressed with IL-4 but not with IFN- ⁇ in cloned T cell lines (Fig. 3b) . This staining pattern also occurred in cells derived from naive T cells.
  • OVA TCR ovalbumin T cell receptor
  • the antibody was also shown to strongly lyse Th2 cells but had only a modest effect on Thl cells in vitro in the presence of complement (see Table 1) .
  • cytotoxic T cell type 1 and 2, or Tel and Tc2 cytotoxic T cell type 1 and 2, or Tel and Tc2
  • Spleen cells from C57BL/6 mice bearing TCR transgene specific for peptide 257-264 of ovalbumin called OT-I cells
  • OT-I cells TCR transgene specific for peptide 257-264 of ovalbumin
  • the cells were then harvested, stimulated and stained as above. While Tc2 cells were strongly positive [Fig. 3d(a)], Tel cells were only weakly stained [Fig. 3d(b)].
  • Example 4 The effect of anti-ST2L antibody in vivo BALB/c mice are genetically highly susceptible to Leishjnania major infection [Liew, F.Y. et al (1993) Leishmania. Adv. Parasitol. 32, 161-259]. Disease progression and resistance are associated with the preferential development of Th2 or Thl cells, respectively [Reiner, S.L. et al (1995) Ann. Rev. Immunol. 13, 151-177].
  • Draining lymph node cells (n 10) from the anti-ST2L- treated mice produced significantly more IFN- ⁇ , but less IL-4 and IL-5 compared with cells from control IgG-treated mice (Fig. 4b) . IL-12 levels were not affected. Serum from anti-ST2L-treated mice produced markedly more IgG2a and similar amounts of IgGl leishmanial-specific antibody compared with serum from the control mice (Fig. 4c) .
  • Collagen-induced arthritis (CIA) in susceptible DBA/1 mice is a predominantly Thl-mediated disease [see Simon, A.K. et al (1994) Proc. Natl. Acad. Sci. USA 91, 8562- 8566], the immunopathogenesis of which closely resembles clinical rheumatoid arthritis [see Trentham D.E. et al (1977) J. Exp. Med. 146, 857-868; Courtenay, J.S. et al (1980) Nature (London) 283, 666-668].
  • the present inventors therefore examined whether administration of anti-ST2L antibody could modify CIA.
  • mice which received anti-ST2L antibody were markedly enhanced in mice which received anti-ST2L antibody, compared with controls injected with normal IgG
  • mice On stimulation with collagen in vitro , spleen cells from the antibody-treated mice also produced significantly more IFN- ⁇ and IL-6 compared with cells from control mice (Fig. 5d) . IL-4 and IL-5 were not detected ( ⁇ 20 pg/ml) .
  • the anti-ST2L antibody also markedly exacerbated LPS- induced mortality in BALB/c mice (Table 2) . This was accompanied by elevated concentrations of serum IFN- ⁇ , tumour necrosis factor (TNF ) and IL-6.
  • mice female BALB/c, 8 weeks old from Harlan Ltd, UK
  • mice were immunised subcutaneously with 2 ⁇ g of the house dust mite antigen, Der pi (from ALK, Horsholm, Denmark) in aluminium hydroxide (from Pierce and Warriner, Chester, UK) as adjuvant on day 0.
  • Mice were injected intraperitoneally with the anti-ST2L antibody (250 ⁇ g/mouse/day in PBS) or normal IgG on day -1, 0, 1,4,8,11, 15, 18, 22 and 25.
  • Monoclonal anti-ST2L antibody has now been developed. This has been achieved by a standard hybridoma technique (see p7) . Spleen cells from a rat immunised with the ST2L peptide were fused with NSO cells. Anti-ST2L producing clones were then screened by ELISA and by FAQS analysis using cloned Th2 cells. Monoclonal antibody was then produced in bulk tissue culture.
  • Rabbit anti-human ST2L polyclonal antibody was also produced.
  • a rabbit was immunised with a peptide corresponding to human ST2L (see p6, residues 264-282) according to the protocol detailed on pl3.
  • the antibody stains human Th2 but not Thl cells.
  • mice were injected ip with 18 mg/kg of LPS on day 0. They were also injected ip daily with 400 ⁇ g/mouse of antibody or normal IgG from day -1. Serum were obtained from tail vein 2 h after LPS injection and pooled for cytokine assays by ELISA. Experiments were terminated at 72 h according to the UK Home Office guideline. Two sample T-test was used for cytokine comparisons and two-tail log- rank test for survival analysis between the two groups of mice. *p ⁇ 0.05; **p ⁇ 0.02. There was no difference in the IL-10 or IL-12 concentrations between the two groups, IL-4 and IL-5 were not detected ( ⁇ 40 pg/ml) . Results are representative of 2 experiments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une forme de la protéine ST2 liée à une membrane appelée protéine ST2L, et particulièrement le développement de réactifs tels que des anticorps, des ligands, des agonistes et /ou antagonistes spécifiques à ST2L que l'on peut utiliser pour l'identification ou la séparation de cellules, le criblage de médicaments et le traitement des affections comme l'inflammation, l'allergie et les infections.
PCT/GB1998/003913 1997-12-24 1998-12-24 Reactifs specifiques a st2l et leurs utilisations Ceased WO1999034217A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19750/99A AU1975099A (en) 1997-12-24 1998-12-24 Reagents specific for st2l and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9727172.0A GB9727172D0 (en) 1997-12-24 1997-12-24 Reagents specific for st2l and uses therefor
GB9727172.0 1997-12-24

Publications (1)

Publication Number Publication Date
WO1999034217A1 true WO1999034217A1 (fr) 1999-07-08

Family

ID=10824117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/003913 Ceased WO1999034217A1 (fr) 1997-12-24 1998-12-24 Reactifs specifiques a st2l et leurs utilisations

Country Status (3)

Country Link
AU (1) AU1975099A (fr)
GB (1) GB9727172D0 (fr)
WO (1) WO1999034217A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079844A3 (fr) * 2004-02-17 2005-11-24 Schering Corp Procedes pour moduler l'activite de la cytokine et reactifs associes
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
US7452980B2 (en) * 1999-09-24 2008-11-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of immune disorders
US7655415B2 (en) 2002-05-09 2010-02-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
WO2011127412A2 (fr) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et analyses
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
WO2012113813A1 (fr) * 2011-02-23 2012-08-30 F. Hoffmann-La Roche Ag Anticorps contre il33r humain et ses utilisations
KR20150013167A (ko) * 2012-05-18 2015-02-04 암젠 인크 St2 항원 결합 단백질
JP2015516817A (ja) * 2012-04-30 2015-06-18 ヤンセン バイオテツク，インコーポレーテツド Ｓｔ２ｌ拮抗物質及び使用方法
WO2015164354A1 (fr) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions et méthodes pour le traitement de troubles liés aux cytokines
AU2013204182B2 (en) * 2010-04-09 2016-09-15 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
US9886553B2 (en) 2008-04-18 2018-02-06 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
US10067146B2 (en) 2006-04-24 2018-09-04 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
AU2016269576B2 (en) * 2010-04-09 2018-11-08 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
US10203339B2 (en) 2006-05-01 2019-02-12 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
CN112457392A (zh) * 2021-01-27 2021-03-09 天津奇云诺德生物医学有限公司 一种可溶性st2蛋白抗原决定簇多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KUMAR S. ET AL.: "ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and HUVECs but does not bind IL-1.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 46, 17 November 1995 (1995-11-17), pages 27905 - 13, XP000604708 *
LÖHNING M. ET AL.: "T1/ST2 is preferentially expressed on murine Th2 cells, independent of IL-4, IL-5, and IL-10, and important for Th2 effector function.", PROC. NATL. ACAD. SCI. USA, vol. 95, no. 12, June 1998 (1998-06-01), pages 6930 - 35, XP002101454 *
XU D. ET AL.: "Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells.", J. EXP. MED., vol. 187, no. 5, 2 March 1998 (1998-03-02), pages 787 - 794, XP002101601 *
YOSHIDA K. ET AL.: "Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies", HYBRIDOMA, NEW YORK, USA, vol. 14, no. 5, October 1995 (1995-10-01), pages 419 - 27, XP002101452 *

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444987B2 (en) 1999-09-24 2013-05-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of immune disorders
US7452980B2 (en) * 1999-09-24 2008-11-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of immune disorders
US7972797B2 (en) 1999-09-24 2011-07-05 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of immune disorders
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
US9857379B2 (en) 2000-11-09 2018-01-02 The Brigham And Women's Hospital Inc. Methods for treatment of cardiovascular disease
US8871452B2 (en) 2000-11-09 2014-10-28 The Brigham And Women's Hospital, Inc. Methods for treatment of cardiovascular disease
US8530173B2 (en) 2000-11-09 2013-09-10 The Brigham And Women's Hospital, Inc. Methods for treatment of cardiovascular disease
US7985558B2 (en) 2000-11-09 2011-07-26 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
US8748116B2 (en) 2002-05-09 2014-06-10 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
US8734769B2 (en) 2002-05-09 2014-05-27 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
US9851362B2 (en) 2002-05-09 2017-12-26 The Brigham & Women's Hosptial, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
US7655415B2 (en) 2002-05-09 2010-02-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
US7989210B2 (en) 2002-05-09 2011-08-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
US10788500B2 (en) 2002-05-09 2020-09-29 Brigham & Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
US8597958B2 (en) 2002-05-09 2013-12-03 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
WO2005079844A3 (fr) * 2004-02-17 2005-11-24 Schering Corp Procedes pour moduler l'activite de la cytokine et reactifs associes
US9970944B2 (en) 2004-02-17 2018-05-15 Merck Sharp & Dohme Corp. Methods of modulating cytokine activity; related reagents
EP2283860A3 (fr) * 2004-02-17 2013-06-05 Merck Sharp & Dohme Corp. Utilisation d'interleukine 33 (il-33) et du complexe recepteur il-33
AU2005215528B2 (en) * 2004-02-17 2009-04-30 Merck Sharp & Dohme Corp. Use for interleukin-33 (IL33) and the IL-33 receptor complex
US10067146B2 (en) 2006-04-24 2018-09-04 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
US11016103B2 (en) 2006-04-24 2021-05-25 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
US10203339B2 (en) 2006-05-01 2019-02-12 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
US9886553B2 (en) 2008-04-18 2018-02-06 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
US11170896B2 (en) 2008-04-18 2021-11-09 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
AU2013204182B2 (en) * 2010-04-09 2016-09-15 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
AU2016269576B2 (en) * 2010-04-09 2018-11-08 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
US9150654B2 (en) 2010-04-09 2015-10-06 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
WO2011127412A2 (fr) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et analyses
EP3848394A1 (fr) * 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et dosages
AU2011237359B2 (en) * 2010-04-09 2016-02-04 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
CN106620692B (zh) * 2010-04-09 2021-04-09 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
CN103154027A (zh) * 2010-04-09 2013-06-12 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
EP3050901A1 (fr) * 2010-04-09 2016-08-03 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et dosages
AU2019200747B2 (en) * 2010-04-09 2020-09-17 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
US10745484B2 (en) 2010-04-09 2020-08-18 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
CN106620692A (zh) * 2010-04-09 2017-05-10 重症监护诊断股份有限公司 可溶性人st‑2抗体和分析法
RU2625014C2 (ru) * 2010-04-09 2017-07-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
EP2556090A4 (fr) * 2010-04-09 2013-08-21 Critical Care Diagnostics Inc Anticorps st-2 humains solubles et analyses
EP3434694A1 (fr) * 2010-04-09 2019-01-30 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et dosages
CN103562224A (zh) * 2011-02-23 2014-02-05 弗·哈夫曼-拉罗切有限公司 针对人il33r的抗体及其用途
US9309319B2 (en) 2011-02-23 2016-04-12 Hoffmann-La Roche Inc. Antibodies against human IL33R and uses thereof
JP2014508520A (ja) * 2011-02-23 2014-04-10 エフ．ホフマン−ラ ロシュ アーゲー ヒトｉｌ３３ｒに対する抗体およびその使用
KR102003075B1 (ko) * 2011-02-23 2019-07-23 에프. 호프만-라 로슈 아게 인간 il33r에 대한 항체 및 이의 용도
KR20140020923A (ko) * 2011-02-23 2014-02-19 에프. 호프만-라 로슈 아게 인간 il33r에 대한 항체 및 이의 용도
WO2012113813A1 (fr) * 2011-02-23 2012-08-30 F. Hoffmann-La Roche Ag Anticorps contre il33r humain et ses utilisations
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
KR102147140B1 (ko) 2012-04-30 2020-08-25 얀센 바이오테크 인코포레이티드 St2l 길항제 및 사용 방법
JP2015516817A (ja) * 2012-04-30 2015-06-18 ヤンセン バイオテツク，インコーポレーテツド Ｓｔ２ｌ拮抗物質及び使用方法
CN107098973A (zh) * 2012-04-30 2017-08-29 詹森生物科技公司 St2l拮抗剂及使用方法
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
JP2018064560A (ja) * 2012-04-30 2018-04-26 ヤンセン バイオテツク，インコーポレーテツド Ｓｔ２ｌ拮抗物質及び使用方法
JP2019162136A (ja) * 2012-04-30 2019-09-26 ヤンセン バイオテツク，インコーポレーテツド Ｓｔ２ｌ拮抗物質及び使用方法
US10450377B2 (en) 2012-04-30 2019-10-22 Janssen Biotech, Inc. ST2L antagonists and methods of use
KR20200037886A (ko) * 2012-04-30 2020-04-09 얀센 바이오테크 인코포레이티드 St2l 길항제 및 사용 방법
US9951137B2 (en) 2012-04-30 2018-04-24 Janssen Biotech, Inc. ST2L antagonists and methods of use
JP2016180001A (ja) * 2012-05-18 2016-10-13 アムジェン インコーポレイテッド Ｓｔ２抗原結合タンパク質
US10227414B2 (en) 2012-05-18 2019-03-12 Amgen Inc. ST2 antigen binding proteins
US9382318B2 (en) 2012-05-18 2016-07-05 Amgen Inc. ST2 antigen binding proteins
KR102161460B1 (ko) 2012-05-18 2020-10-07 암젠 인크 St2 항원 결합 단백질
KR20150013167A (ko) * 2012-05-18 2015-02-04 암젠 인크 St2 항원 결합 단백질
JP2015523967A (ja) * 2012-05-18 2015-08-20 アムジェン インコーポレイテッド Ｓｔ２抗原結合タンパク質
US11059895B2 (en) 2012-05-18 2021-07-13 Amgen Inc. ST2 antigen binding proteins
US9982054B2 (en) 2012-05-18 2018-05-29 Amgen Inc. ST2 antigen binding proteins
JP2022106790A (ja) * 2012-05-18 2022-07-20 アムジェン インコーポレイテッド Ｓｔ２抗原結合タンパク質
US11965029B2 (en) 2012-05-18 2024-04-23 Amgen Inc. ST2 antigen binding proteins
WO2015164354A1 (fr) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions et méthodes pour le traitement de troubles liés aux cytokines
CN112457392A (zh) * 2021-01-27 2021-03-09 天津奇云诺德生物医学有限公司 一种可溶性st2蛋白抗原决定簇多肽及其应用
CN112457392B (zh) * 2021-01-27 2021-04-27 天津奇云诺德生物医学有限公司 一种可溶性st2蛋白抗原决定簇多肽及其应用

Also Published As

Publication number Publication date
GB9727172D0 (en) 1998-02-25
AU1975099A (en) 1999-07-19

Similar Documents

Publication Publication Date Title
WO1999034217A1 (fr) Reactifs specifiques a st2l et leurs utilisations
CA1337518C (fr) Anticorps monoclonaux diriges contre le tnf-–, des hybridomes produisant ces anticorps et une methode de purification de la tnf-–
YOSHIOKA et al. Polyclonal expansion of TCRBV2‐and TCRBV6‐bearing T cells in patients with Kawasaki disease
EP0394302B1 (fr) ADN CODANT L'ALPHA-SOUS-UNITE OU FRAGMENT DE CELLE-CI D'UN RECEPTEUR IgE
JP4949859B2 (ja) インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用
EP0398327B2 (fr) Protéine de liaison II au facteur de nécrose tumorale, sa purification et anticorps spécifiques
Aldebert et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators
US20030124624A1 (en) Monoclonal antibody and method and kit for immunoassay of soluble human ST2
HK1040531A1 (en) Method for producing a mammalian cytokine synthesis inhibitory factor
KR100361449B1 (ko) 리서스D항원들(RhesusDantigens)에특정적인항원결합구조들을형성할수있는폴리펩티드들,그것들을인코딩한DNA,그리고그것들의제조방법및용도
Sioud et al. Characterization of naturally occurring autoantibodies against tumour necrosis factor‐alpha (TNF‐α): in vitro function and precise epitope mapping by phage epitope library
EP0786002B1 (fr) Isoforme intracellulaire de l'antagoniste du recepteur de l'interleukine-1
EP0851030B1 (fr) PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
Persechini et al. The primary structure of the lymphocyte pore-forming protein perforin: partial amino acid sequencing and determination of isoelectric point
US5736340A (en) Secreted Mac-2-binding glycoprotein
US5688656A (en) Cytokine-induced marker for inflammatory response
US5698204A (en) Recombinant allergenic proteins from ragweed pollen
Bost et al. In vivo treatment with anti‐interleukin‐13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice
US5434247A (en) Peptides for inducing monocyte cytotoxicity in diagnostics
WO1993007485A1 (fr) Regions de structures d'immunoglobulines rares associees a la maladie chez l'homme
Levin et al. The cloned C-terminal region of a Trypanosoma cruzi P ribosomal protein harbors two antigenic determinants
JP3065628B2 (ja) ヒト免疫グロブリン遺伝子関連ｄｎａ断片及び該ｄｎａ断片を用いる診断方法
Sibille et al. Fc alpha-receptor expression on the myelomonocytic cell line THP-1: comparison with human alveolar macrophages
CN105388299B (zh) 人类细胞因子ccdc134在自身免疫性疾病中的应用
Stiemer et al. A common epitope on human tumor necrosis factor alpha and the autoantigen ‘S-antigen/arrestin’induces TNF-α production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA